Education
About Us
Working with TipRanks
Follow Us
Intellia Therapeutics (NTLA)
NASDAQ:NTLA
Earnings Data
Report Date
Jul 31, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
-1.03Last Year’s EPS
-1.52Same Quarter Last Year
Moderate Buy
Based on 21 Analysts Ratings
Earnings Call Summary
Earnings Call Date:May 08, 2025
|% Change Since: 10.97%
|Next Earnings Date:Jul 31, 2025
Earnings Call Sentiment|Positive
Intellia Therapeutics showed strong progress in its clinical pipeline with advancements in Phase 3 studies and key regulatory milestones. Financially, the company maintains a robust position despite some short-term revenue declines and restructuring costs, which are expected to bring future savings. The overall sentiment is positive, driven by significant clinical and regulatory advancements outweighing the financial challenges.Company Guidance
In the first quarter of 2025, Intellia achieved significant milestones, including dosing the first patients in Phase 3 studies for hereditary angioedema (HAE) and ATTR amyloidosis with polyneuropathy. Enrollment in the global Phase 3 HAELO study is progressing rapidly, with completion expected by the end of the third quarter. The Phase 3 MAGNITUDE study for ATTR with cardiomyopathy is also ahead of schedule, with over 90 active sites and cumulative enrollment expected to exceed 550 patients by year-end. Financially, Intellia reported cash, cash equivalents, and marketable securities of approximately $707.1 million as of March 31, 2025, down from $861.7 million at the end of 2024. The company maintains a strong balance sheet, with a quarterly cash use estimate of $95 million for 2025 and 2026, and expects its current cash to fund operations into the first half of 2027. Revenue for Q1 2025 was $16.6 million, with R&D expenses of $108.4 million and G&A expenses of $29 million. The company is on track to file its first BLA in 2026, with a focus on bringing one-time therapies to market efficiently.Progress in Phase 3 Studies
Intellia dosed the first patient in their Phase 3 study for hereditary angioedema (HAE) and for hereditary ATTR with polyneuropathy. Enrollment in the global Phase 3 HAELO study for HAE is progressing ahead of schedule, and the Phase 3 MAGNITUDE study for ATTR with cardiomyopathy is also ahead of schedule with over 90 sites actively enrolling.
Regulatory Milestones
The FDA granted Intellia the RMAT designation for nexiguran ziclumeran (nex-z) for the treatment of ATTR with cardiomyopathy, adding to prior RMAT designations for ATTR with polyneuropathy and NTLA-2002 in HAE.
Strong Financial Position
Intellia maintains a solid balance sheet with cash, cash equivalents, and marketable securities totaling approximately $707.1 million as of March 31, 2025. The company expects a year-over-year decline in GAAP operating expenses of between 5% and 10% and has sufficient funds to operate into the first half of 2027.
Positive Clinical Data
Upcoming data presentations include two-year follow-up data from NTLA-2002 at the European Academy of Allergy and Clinical Immunology Congress and longer-term data from the Phase 1 study for ATTR amyloidosis, extending the durability window out to at least three years.
NTLA Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
NTLA Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 08, 2025 | $7.29 | $8.28 | +13.58% |
Feb 27, 2025 | $10.80 | $10.86 | +0.56% |
Nov 07, 2024 | $16.06 | $16.00 | -0.37% |
Aug 08, 2024 | $21.31 | $22.38 | +5.02% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Intellia Therapeutics (NTLA) report earnings?
Intellia Therapeutics (NTLA) is schdueled to report earning on Jul 31, 2025, TBA Not Confirmed.
What is Intellia Therapeutics (NTLA) earnings time?
Intellia Therapeutics (NTLA) earnings time is at Jul 31, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is NTLA EPS forecast?
NTLA EPS forecast for the fiscal quarter 2025 (Q2) is -1.03.